Nurix Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
March 04 2021 - 8:01PM
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical
company developing targeted protein modulation drugs,
today announced the pricing of its underwritten public
offering of 4,500,000 shares of its common stock at a public
offering price of $31.00 per share. The public offering was upsized
from the previously announced size of 4,000,000 shares of its
common stock. All shares of common stock are being offered by
Nurix. The gross proceeds from the offering, before deducting
underwriting discounts and commissions and other offering expenses,
are expected to be $139.5 million. In addition, Nurix has granted
the underwriters a 30-day option to purchase up to an additional
675,000 shares of its common stock at the public offering price,
less underwriting discounts and commissions. The offering is
expected to close on March 9, 2021, subject to the satisfaction of
customary closing conditions.
J.P. Morgan, Piper Sandler and Stifel are acting
as the joint bookrunning managers for the proposed offering. RBC
Capital Markets and Needham & Company are acting as the lead
managers for the proposed offering.
A registration statement relating to the sale of
these securities has been filed with, and declared effective by,
the Securities and Exchange Commission (“SEC”). The offering is
being made only by means of a prospectus. A copy of the final
prospectus relating to the offering, when available, may be
obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by
telephone at (866) 803-9204, or via email at
prospectus-eq_fi@jpmchase.com; Piper Sandler & Co., Attention:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN
55402, by telephone at (800) 747-3924, or via email at
prospectus@psc.com; or Stifel, Nicolaus & Company,
Incorporated, Attention: Prospectus Department, One Montgomery
Street, Suite 3700, San Francisco, CA 94104, by telephone at (415)
364-2720, or via email at syndprospectus@stifel.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Nurix Therapeutics,
Inc.
Nurix Therapeutics is a biopharmaceutical
company focused on the discovery, development, and
commercialization of small molecule therapies designed to modulate
cellular protein levels as a novel treatment approach for cancer
and other challenging diseases. Leveraging Nurix’s extensive
expertise in E3 ligases together with its proprietary DNA-encoded
libraries, Nurix has built DELigase, an integrated discovery
platform to identify and advance novel drug candidates targeting E3
ligases, a broad class of enzymes that can modulate proteins within
the cell. Nurix’s drug discovery approach is to either harness or
inhibit the natural function of E3 ligases within the ubiquitin
proteasome system to selectively decrease or increase cellular
protein levels. Nurix’s wholly owned pipeline includes targeted
protein degraders of Bruton’s tyrosine kinase, a B-cell signaling
protein, and inhibitors of Casitas B-lineage lymphoma
proto-oncogene B, an E3 ligase that regulates T cell
activation.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements reflect the current beliefs and
expectations of management and include, but are not limited to,
statements regarding the expected gross proceeds of the offering,
the satisfaction of customary closing conditions related to the
offering and sale of securities, and Nurix’s ability to complete
the offering. All statements other than statements of historical
fact are statements that could be deemed forward-looking
statements. Although Nurix believes that the expectations reflected
in such forward-looking statements are reasonable, it can give no
assurance that such expectations will prove to be correct.
Forward-looking statements are subject to risks and uncertainties
that may cause Nurix’s actual activities or results to differ
significantly from those expressed in any forward-looking
statement, including, without limitation, risks and uncertainties
related to market conditions and the satisfaction of closing
conditions related to the proposed public offering, and the risks
and uncertainties described under the heading “Risk Factors” in
documents Nurix files from time to time with the SEC, including
Nurix’s Annual Report on Form 10-K filed with the SEC on February
16, 2021, the preliminary prospectus for this offering included as
part of the registration statement on Form S-1 related to this
offering filed with the SEC on March 2, 2021, and its future
periodic reports to be filed with the SEC. These forward-looking
statements speak only as of the date of this press release, and
Nurix undertakes no obligation to revise or update any
forward-looking statements to reflect events or circumstances after
the date hereof.
Investor ContactJason Kantor, Ph.D.Nurix
Therapeutics, Inc.jkantor@nurixtx.com
Media ContactElizabeth Wolffe, Ph.D.Wheelhouse
Life Science Advisorslwolffe@wheelhouselsa.com
Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nurix Therapeutics (NASDAQ:NRIX)
Historical Stock Chart
From Apr 2023 to Apr 2024